Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

doi:10.1371/journal.pone.0149722

Article

Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

PloS one - 1 Jan 2016

Chen Yu-Mu, Lai Chien-Hao, Chang Huang-Chih, Chao Tung-Ying, Tseng Chia-Cheng, Fang Wen-Feng, Wang Chin-Chou, Chung Yu-Hsiu, Wang Yi-Hsi, Su Mao-Chang, Liu Shih-Feng, Huang Kuo-Tung, Chen Hung-Chen, Chang Ya-Chun, Lin Meng-Chih

Abstract excerpt

BACKGROUND: Antacid treatments decrease the serum concentrations of first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), although it is unknown whether antacids affect clinical outcomes. As cerebrospinal fluid concentrations of TKIs are much lower than serum concentrations, we hypothesized that this drug-drug interaction might affect the prognosis of patients with de novo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Abstract excerpt

Topics

Related research